Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 6 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Product Highlight – Dukoral

12 Jul 2017
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics

The Drinkable Vaccine against Cholera & enterotoxigenic E.coli (ETEC) Diarrhoea


Clinically proven protective efficacy:
- Up to 85-90% against cholera in the first 6 months3,4,6
- Up to 67% against ETEC in the first 3 months.5

At least one week interval between doses. Primary immunization can be completed as early as 8 days for adults and children over 6 years old (2 required doses) and 15 days for children 2-6 years (3 required doses).1

Onset of protection starts 7 days after completion of immunisation. The vaccination course should be completed at least one week before traveling.1

Good safety profile with most frequently reported adverse reactions occurred at similar frequencies in vaccine and placebo group in studies.

References:

1. DUKORAL full prescribing information (SV40398_MY).
2. Clements JD, Finkelstein RA. Demonstration of shared and unique immunological determinants in enterotoxins from Vibrio cholerae and Escherichia coli. Infect Immun 1978;22:709–13.
3. World Health Organization. Use of Oral Cholera Vaccine in Humanitarian Emergencies. http://www.who.int/cholera/vaccines/OCV_in_humanitarian_emergencies_15Jan2014.pdf.
4. Clemens JD, Sack DA, Harris RJ et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 1986, 2:124-7.
5. Clemens JD., et al. Cross-protection by B subunit whole-cell cholera vaccine against diarrhoea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: result of a large-scale field trial. J Infect Dis 1988; 158:372-77.
6.
World Health Organization. Cholera vaccines WHO position paper. Weekly Epidemiologic Record (WER). No 13, 2010, 85, 117-128 http://www.who.int/wer/2010/wer8513.pdf.

Further information is available in section 12b, New in This Issue and mims.com
Full prescribing information is available upon request.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 6 days ago
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.